JP2003500352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003500352A5 JP2003500352A5 JP2000619411A JP2000619411A JP2003500352A5 JP 2003500352 A5 JP2003500352 A5 JP 2003500352A5 JP 2000619411 A JP2000619411 A JP 2000619411A JP 2000619411 A JP2000619411 A JP 2000619411A JP 2003500352 A5 JP2003500352 A5 JP 2003500352A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- angiogenesis
- diphosphonic acid
- hydroxy
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000033115 angiogenesis Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 229940122361 Bisphosphonate Drugs 0.000 description 8
- 150000004663 bisphosphonates Chemical class 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 5
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229960004276 zoledronic acid Drugs 0.000 description 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- -1 methyl (Pentylamino) -propylidene-bisphosphonic acid Chemical compound 0.000 description 3
- 229960003978 pamidronic acid Drugs 0.000 description 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- PMXAPNNYCFBALB-UHFFFAOYSA-N (1-hydroxy-1-phosphono-3-pyrrolidin-1-ylpropyl)phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCN1CCCC1 PMXAPNNYCFBALB-UHFFFAOYSA-N 0.000 description 1
- RDFHOSXBGDLRQF-UHFFFAOYSA-N (2-anilino-1-phosphono-2-sulfanylideneethyl)phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)C(=S)NC1=CC=CC=C1 RDFHOSXBGDLRQF-UHFFFAOYSA-N 0.000 description 1
- HLNJFEXZDGURGZ-UHFFFAOYSA-M 1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1 HLNJFEXZDGURGZ-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical class C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VADUXZPJGJBSLQ-UHFFFAOYSA-N [1-hydroxy-3-(1-methylpyridin-1-ium-3-yl)-1-phosphonopropyl]phosphonic acid;hydroxide Chemical compound [OH-].C[N+]1=CC=CC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=C1 VADUXZPJGJBSLQ-UHFFFAOYSA-N 0.000 description 1
- QWCNOXMFNSYEKF-UHFFFAOYSA-N [1-hydroxy-3-[methyl(2-phenylsulfanylethyl)amino]-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(O)(P(O)(O)=O)CCN(C)CCSC1=CC=CC=C1 QWCNOXMFNSYEKF-UHFFFAOYSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- JFGHPLSPUGOSLV-UHFFFAOYSA-L disodium;[3-(dimethylamino)-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].CN(C)CCC(O)(P(O)(O)=O)P([O-])([O-])=O JFGHPLSPUGOSLV-UHFFFAOYSA-L 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9911926.5A GB9911926D0 (en) | 1999-05-21 | 1999-05-21 | Organic compounds |
| GB9911926.5 | 1999-05-21 | ||
| GB9925131.6 | 1999-10-22 | ||
| GBGB9925131.6A GB9925131D0 (en) | 1999-10-22 | 1999-10-22 | Organic compounds |
| PCT/EP2000/004562 WO2000071104A2 (en) | 1999-05-21 | 2000-05-19 | Use of bisphosphonic acids for treating angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500352A JP2003500352A (ja) | 2003-01-07 |
| JP2003500352A5 true JP2003500352A5 (enExample) | 2007-07-05 |
Family
ID=26315578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000619411A Pending JP2003500352A (ja) | 1999-05-21 | 2000-05-19 | 血管形成を処置するためのビスホスホン酸の使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20020142996A1 (enExample) |
| EP (1) | EP1178810B8 (enExample) |
| JP (1) | JP2003500352A (enExample) |
| KR (1) | KR100763064B1 (enExample) |
| CN (1) | CN1202828C (enExample) |
| AT (1) | ATE293450T1 (enExample) |
| AU (1) | AU775079B2 (enExample) |
| BR (1) | BR0010808A (enExample) |
| CA (1) | CA2374049A1 (enExample) |
| DE (1) | DE60019580T2 (enExample) |
| DK (1) | DK1178810T3 (enExample) |
| ES (1) | ES2240106T3 (enExample) |
| HU (1) | HUP0201329A3 (enExample) |
| IL (2) | IL146520A0 (enExample) |
| NO (1) | NO322212B1 (enExample) |
| NZ (1) | NZ515541A (enExample) |
| PL (1) | PL351674A1 (enExample) |
| PT (1) | PT1178810E (enExample) |
| SK (1) | SK16682001A3 (enExample) |
| TW (1) | TWI224504B (enExample) |
| WO (1) | WO2000071104A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1296689T3 (da) * | 2000-06-20 | 2005-11-28 | Novartis Ag | Fremgangsmåde til indgivelse af bisphosphonater |
| EP1591122B1 (en) * | 2000-06-20 | 2012-09-26 | Novartis AG | Method of administering bisphosphonates |
| DE60143964D1 (de) * | 2001-02-06 | 2011-03-10 | Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital | Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose |
| BR0209365A (pt) * | 2001-05-02 | 2004-06-08 | Novartis Ag | Usos farmacêuticos de bisfosfonatos |
| ES2336312T3 (es) * | 2001-07-16 | 2010-04-12 | Universite Paris 13 | Procedimiento de preparacion de derivados de bisfosfonatos. |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| CA2478317A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| BR0308901A (pt) | 2002-05-10 | 2005-01-04 | Hoffmann La Roche | ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose |
| ATE441420T1 (de) * | 2002-12-02 | 2009-09-15 | Innate Pharma | Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen |
| US20060281714A1 (en) * | 2003-07-21 | 2006-12-14 | Johann Zimmermann | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss |
| US7618953B2 (en) † | 2004-02-26 | 2009-11-17 | Zentiva, A.S. | Amorphous forms of risedronate monosodium |
| ES2358269T3 (es) * | 2004-08-23 | 2011-05-09 | Teva Pharmaceutical Industries Ltd | Forma cristalina del ibandronato sódico y procedimientos para su preparación. |
| US7914810B2 (en) | 2005-05-06 | 2011-03-29 | Synthes Usa, Llc | Methods for the in situ treatment of bone cancer |
| PE20070360A1 (es) * | 2005-09-01 | 2007-04-19 | Novartis Ag | Composiciones de liposomas |
| US20070218116A1 (en) * | 2006-03-14 | 2007-09-20 | Schwendener Reto A | Compositions and methods for the treatment of tumors and tumor metastases |
| EP2255199A1 (en) * | 2008-02-19 | 2010-12-01 | Jovesis Inc. | Microparticle compositions to modify cancer promoting cells |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| KR101813728B1 (ko) * | 2009-07-31 | 2017-12-29 | 그뤼넨탈 게엠베하 | 결정화 방법 및 생체이용률 |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| WO2015018659A1 (en) * | 2013-08-05 | 2015-02-12 | Vib Vzw | Glutamine synthetase inhibitors for inhibition of pathological angiogenesis |
| WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4067971A (en) * | 1976-05-13 | 1978-01-10 | The Procter & Gamble Company | Therapeutic composition |
| DE3425812A1 (de) * | 1984-07-13 | 1986-01-16 | Deutsches Krebsforschungszentrum, 6900 Heidelberg | Neue 1-hydroxy-1,1-diphosphonsaeureverbindungen, verfahren zu ihrer herstellung und pharmakologische zubereitungen, insbesondere zur behandlung von knochentumoren |
| IT1187828B (it) * | 1985-05-24 | 1987-12-23 | Gentili Ist Spa | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi |
| DE3623397A1 (de) * | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| GB8618259D0 (en) * | 1986-07-25 | 1986-09-03 | Leo Pharm Prod Ltd | Pharmaceutical compositions |
| US5116864A (en) * | 1991-04-09 | 1992-05-26 | Indiana University Foundation | Method for preventing restenosis following reconfiguration of body vessels |
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
| SE9402001D0 (sv) * | 1994-06-09 | 1994-06-09 | Leiras Oy | Pyridylbisphosphonates for use as a therapeutical agent |
| IT1290444B1 (it) * | 1997-03-27 | 1998-12-03 | Boehringer Mannheim Italia | Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale |
| DE69803291T2 (de) * | 1997-07-22 | 2002-08-08 | Merck & Co Inc | Methoden zur verhinderung von knochenresorption |
| US5994329A (en) * | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP0998934A4 (en) * | 1997-12-25 | 2005-09-14 | Toray Industries | REMEDIES AGAINST INTRAMEDULLARY DISEASES |
| US6416964B2 (en) * | 1998-01-29 | 2002-07-09 | Merck & Co., Inc. | Methods of identifying modulators of kinases responsive to stress |
| WO1999038998A1 (en) * | 1998-01-29 | 1999-08-05 | Merck & Co., Inc. | Methods of identifying modulators of kinases responsive to stress |
| IL125336A0 (en) * | 1998-07-14 | 1999-03-12 | Yissum Res Dev Co | Compositions for inhibition and treatment of restinosis |
| WO2000028982A2 (en) * | 1998-11-19 | 2000-05-25 | The Board Of Trustees For The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
| US6426367B1 (en) * | 1999-09-09 | 2002-07-30 | Efa Sciences Llc | Methods for selectively occluding blood supplies to neoplasias |
| US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
-
2000
- 2000-05-19 EP EP00936760A patent/EP1178810B8/en not_active Revoked
- 2000-05-19 DK DK00936760T patent/DK1178810T3/da active
- 2000-05-19 NZ NZ515541A patent/NZ515541A/xx unknown
- 2000-05-19 HU HU0201329A patent/HUP0201329A3/hu unknown
- 2000-05-19 SK SK1668-2001A patent/SK16682001A3/sk unknown
- 2000-05-19 IL IL14652000A patent/IL146520A0/xx active IP Right Grant
- 2000-05-19 DE DE60019580T patent/DE60019580T2/de not_active Revoked
- 2000-05-19 CN CNB008092117A patent/CN1202828C/zh not_active Expired - Fee Related
- 2000-05-19 CA CA002374049A patent/CA2374049A1/en not_active Abandoned
- 2000-05-19 JP JP2000619411A patent/JP2003500352A/ja active Pending
- 2000-05-19 AU AU52141/00A patent/AU775079B2/en not_active Ceased
- 2000-05-19 BR BR0010808-1A patent/BR0010808A/pt not_active Application Discontinuation
- 2000-05-19 PL PL00351674A patent/PL351674A1/xx not_active Application Discontinuation
- 2000-05-19 ES ES00936760T patent/ES2240106T3/es not_active Expired - Lifetime
- 2000-05-19 AT AT00936760T patent/ATE293450T1/de not_active IP Right Cessation
- 2000-05-19 KR KR1020017014807A patent/KR100763064B1/ko not_active Expired - Fee Related
- 2000-05-19 WO PCT/EP2000/004562 patent/WO2000071104A2/en not_active Ceased
- 2000-05-19 PT PT00936760T patent/PT1178810E/pt unknown
- 2000-05-23 TW TW089109918A patent/TWI224504B/zh not_active IP Right Cessation
-
2001
- 2001-11-15 IL IL146520A patent/IL146520A/en not_active IP Right Cessation
- 2001-11-19 NO NO20015638A patent/NO322212B1/no unknown
- 2001-11-20 US US09/989,577 patent/US20020142996A1/en not_active Abandoned
-
2004
- 2004-03-24 US US10/807,736 patent/US20040176327A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4722375B2 (ja) | ビホスホネートの投与法 | |
| AU2002257802B2 (en) | Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer | |
| CA2427161C (en) | Use of bisphosphonates for pain treatment | |
| EP1178810B1 (en) | Use of bisphosphonic acids for treating angiogenesis | |
| AU2002217061A1 (en) | Use of bisphosphonates for pain treatment | |
| AU2001274109A1 (en) | Method of administering bisphosphonates | |
| CA2501381A1 (en) | Method of administering bisphosphonates | |
| AU2002257802A1 (en) | Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer | |
| EP1591122A1 (en) | Method of administering bisphosphonates | |
| RU2261100C2 (ru) | Применение бисфосфоновых кислот для лечения ангиогенеза | |
| TH51552A (th) | การใช้กรดบิสฟอสโฟนิคสำหรับการบำบัดแอนจิโอจีนีซิส | |
| TH57795A (th) | การใช้บิสฟอสฟอเนททางยา |